Literature DB >> 22083001

Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments.

Rossa E Brugha1, Jane C Davies.   

Abstract

Pseudomonas aeruginosa is the most problematic organism in patients with cystic fibrosis. This article reviews its pathogenic mechanisms, with particular relevance to the pathophysiology of the cystic fibrosis airway, and recent advances in therapeutic approaches.

Entities:  

Mesh：

Year:  2011        PMID： 22083001     DOI： 10.12968/hmed.2011.72.11.614

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  9 in total

1.  Complete genome of Pseudomonas aeruginosa phage PA26.

Authors:  Min Soo Kim; Kyung Eun Cha; Heejoon Myung
Journal:  J Virol       Date:  2012-09       Impact factor: 5.103

2.  Pseudomonas aeruginosa directly shunts β-oxidation degradation intermediates into de novo fatty acid biosynthesis.

Authors:  Yanqiu Yuan; Jennifer A Leeds; Timothy C Meredith
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

Review 3.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  CXCR1 Regulates Pulmonary Anti-Pseudomonas Host Defense.

Authors:  M Carevic; H Öz; K Fuchs; J Laval; C Schroth; N Frey; A Hector; T Bilich; M Haug; A Schmidt; S E Autenrieth; K Bucher; S Beer-Hammer; A Gaggar; M Kneilling; C Benarafa; J L Gao; P M Murphy; S Schwarz; B Moepps; D Hartl
Journal:  J Innate Immun       Date:  2016-03-08       Impact factor: 7.349

5.  Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.

Authors:  Keith Poole; Christie Gilmour; Maya A Farha; Erin Mullen; Calvin Ho-Fung Lau; Eric D Brown
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa.

Authors:  Vincenzo Luca; Annarita Stringaro; Marisa Colone; Alessandro Pini; Maria Luisa Mangoni
Journal:  Cell Mol Life Sci       Date:  2013-03-16       Impact factor: 9.261

7.  AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa.

Authors:  Calvin Ho-Fung Lau; Thomas Krahn; Christie Gilmour; Erin Mullen; Keith Poole
Journal:  Microbiologyopen       Date:  2014-12-01       Impact factor: 3.139

8.  Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.

Authors:  Alaya Mikalauskas; Michael D Parkins; Keith Poole
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

9.  Structural model of FeoB, the iron transporter from Pseudomonas aeruginosa, predicts a cysteine lined, GTP-gated pore.

Authors:  Saeed Seyedmohammad; Natalia Alveal Fuentealba; Robert A J Marriott; Tom A Goetze; J Michael Edwardson; Nelson P Barrera; Henrietta Venter
Journal:  Biosci Rep       Date:  2016-04-27       Impact factor: 3.840
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.